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Introduction. The Cervical Cancer (CC) Prevention Programme includes 3 phases: basic (Pap smear collection), 
diagnostic (Pap smear evaluation) and in-depth (colposcopy/biopsy in case of abnormal smear test findings). The 
Programme service providers are subject to an external audit and this publication’s objective is to analyse its results 
from 2016 and the first half of 2017.
Materials and methods. The audit of the Programme performance in the period 01.01.2016–30.06.2017 was carried 
out by external auditors by way of personal visits to the offices of the service providers and by way of direct data  
retrieval. The audit covered 12% (198) of the basic phase, 100% (66) of the diagnostic phase and 100% (62) of the 
in-depth phase facilities. The Polish National Health Fund (NHF) did not make available the routinely collected data 
for the purpose of audit. Audit data collected in the developed protocols were analysed. 
Results. The number of Pap smears (2,028,988) and the number of colposcopies (13,636) outside the Programme was, 
respectively, more than two and three times higher than in the Programme (cytology — 801,640, colposcopy — 3929). 
The performance of the procedures (Programme vs outside the Programme) was highly variable depending on the 
provider. The percentage of Pap smears unsuitable for evaluation did not differ significantly between gynaecologists 
and midwives. All audited cytological laboratories carried out rescreening of samples. Biopsy was not performed in 
11% (2016) and 15% (2017) of colposcopy laboratories. Inaccuracies were found in 19% (61) of the audit protocols.
Discussion. Significantly higher number of procedures performed outside the Programme results from lower renu-
meration of procedures within the Programme. Variable provider's preferences in the mode of procedures execution 
indicates that with the use of appropriate organisational solutions it would be possible to reduce opportunistic 
screening, which is of unknown quality. The quality of Pap smear sample collection in the case of gynaecologists and 
midwives is the same, but the number of primary care provider (PCP) facilities where midwives collect smears is very 
limited. The inaccuracies noted in the audit protocols indicate that the lack of access to data collected by the National 
Health Fund decreased the quality of the audit carried out and the reliability of the data obtained.
Conclusions. Restoring full access to data collected by the NHF is crucial for the Programme audit quality. Measures 
should be implemented to reduce opportunistic screening and shift the stream of tests to the Programme (both at the 
basic and at the in-depth phase), and to increase the availability of tests in PCP facilities through training for midwives.
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Introduction
The objective of the Cervical Cancer Prevention Pro-
gramme in Poland, implemented in 2006, is to further 
reduce the incidence and mortality of cervical cancer in 
women [1]. 
Under the Programme, each insured Polish woman aged 
25 to 59 is entitled to a free of charge Pap smear test if she 
has not received it within the Programme in the last 3 years.
The service providers perform the Programme in 3 pha-
ses:
1) basic phase: collection of cervical material for cytological 
screening in the framework of: 
a)  outpatient specialist care in the field of obstetrics 
and gynaecology, as consultation from the catalo-
gue of separate specialised services;
b) primary health care provided by PCP midwives;
2) diagnostic phase: performing microscopic evaluation of 
cytological material sent by the diagnostic phase pro-
vider of the Programme and reporting in the computer 
system;
3) in-depth diagnostic phase: colposcopy or colposcopy 
with targeted biopsy and histopathological examina-
tion in women with abnormal results of Pap smear test 
obtained within the Programme.
Service providers of each phase must meet the requ-
irements set out in the regulation of the Minister of Health, 
Journal of Laws of 2016 pos. 1372, Journal of Laws of 2016 
pos. 1743 and the order of the President of the National He-
alth Fund (NHF) no. 81/2013/DSOZ concerning the detailed 
criteria for selection of healthcare service providers such as 
healthcare programs.
The tests carried out under the Programme are unlimi-
ted and financed by the NHF. Data concerning all medical 
services provided under the Programme are collected in 
the Information System for Prevention Monitoring (SIMP), 
which is an electronic database accessible for every heal-
thcare provider.
In 2017, there were 1663 service providers performed 
the basic phase, of which 1602 were outpatient specialist 
care institutions in the field of obstetrics and gynaecology 
and 61 PCP facilities, 66 facilities contracted for the perfor-
mance of the diagnostic phase, and 62 providers contracted 
for the performance in-depth diagnostic phase.
In 2017, the coordination of the Programme in Poland 
was carried out by the Central Coordination Centre (COK — 
Centralny Ośrodek Koordynujący) within the Department of 
Cancer Prevention,The Maria Sklodowska-Curie Institute — 
Oncology Center, Warsaw, Poland, based on a contract with 
the Ministry of Health. The tasks of COK included, among 
others, quality control of services provided at each phase of 
the Programme in 2016 and the first half of 2017.
According to the European Guidelines for Quality As-
surance in Cervical Cancer Screening [2], quality control of 
cytological screening is one of the key elements for ensuring 
the effectiveness of the Programme. In accordance with 
the Guidelines, the results of the quality control should be 
published periodically. The objective of this publication is 
to analyse the results of external audit of the providers of 
the Cervical Cancer Prevention Programme in Poland (as 
one of the elements of the Programme quality control) in 
2016 and the first half of 2017.
The specific objectives were:
 — Evaluation of the preparation of facilities (e.g. equip-
ment, organisation of the facility, qualifications of em-
ployees, procedures in place) for the implementation of 
tasks resulting from the Programme. 
 — Comparison of the number of tests performed under the 
organised Programme to the number of tests performed 
under opportunistic screening.
 — Evaluation of the quality of the smears taken depending 
on the profession (gynaecologist or midwife).
 — Analysing follow-up of patients with positive Pap smear 
findings.
 — Evaluation of the current method of conducting audits 
of facilities implementing the Cervical Cancer Preven-
tion Programme.
The research theses were:
 — The majority of facilities implementing the Programme 
at the basic, diagnostic and in-depth stages are prepa-
red in terms of equipment, organisation of the facility, 
qualifications of their employees, procedures in place 
for the performance of tasks resulting from the contract. 
 — Both at the basic and in-depth stages, the test perfor-
med in patients outside the Prevention Programme 
outnumber the tests within the Programme.
 — The quality of Pap smears taken by midwives and gy-
naecologists, measured as a percentage of the results 
unsuitable for evaluation, is statistically the same.
 — Some patients with positive results of cytological test 
in the Programme perform further diagnostics beyond 
the in-depth stage of the Programme or do not perform 
it at all. 
 — The current way which the facilities implementing the 
Cervical Cancer Prevention Programme are audited, dic-
tated by the lack of access to data collected in SIMP for 
COK employees and auditors is insufficient and requires 
fundamental changes.
Material and methods 
Due to the lack of access to the SIMP for COK employees 
by the National Health Fund, a decision was made to carry 
out audits by way of personal visits of inspectors to the 
offices of the service providers and to obtain data directly.
The contractor for the audit was selected through an 
open tender procedure. The audit was carried out by 14 
auditors from 12 October to 28 November, 2017.
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The audit covered 12% (198) of the basic phase facilities, 
selected at random, 100% (66) of the diagnostic phase and 
100% (62) of the in-depth phase.
The auditors collected data in audit reports based on 
the documentation of the service providers, data obtained 
from SIMP at the service provider level and the electronic 
systems of service providers. The adoption of this mode of 
data collection was caused by the lack of access to SIMP from 
the level of COK and the auditors themselves. 
At various stages, the scope of the audit included ana-
lysis of, among other things:
1. Basic phase
 — Working hours and the test result waiting time
 — Qualifications of the staff employed
 — Equipment of the lab rooms and the equipment used 
in Pap smear tests
 — Methods of marking the slides and archiving the results
 — Results of collected cervical screening samples
2. Diagnostic phase
 — Number of Pap smears assessed within and outside the 
Programme
 — Results of Pap smear tests within the Programme
 — The conditions of providing services guaranteed as per 
the regulations of the Minister of Health, Journal of Ri-
ghts no. 2016 pos. 1372, and Journal of Rights no. 2016 
pos. 1743, satisfied by the personnel and the laboratory
3. In-depth diagnostics phase
 — Facility’s work organisation
 — Number of targeted biopsies performed within the 
Programme 
 — Equipment in the lab rooms.
Statistical methods
Continuous variables were described using mean, me-
dian and range (minimum, maximum). Contingency tables 
were used to describe categorised variables. The linear re-
lationship between continuous variables was investigated 
using Spearman’s rank correlation coefficient. All tests were 
performed at statistical significance of 0.05. Data analysis 
was conducted with the Stata statistical package, ver. 13.1 
(Stata Corporation, College Station, Texas, USA).
Results
Basic phase
185 out of 1602 facilities implementing the Programme 
under a contract for outpatient specialist care in the field 
of obstetrics and gynaecology and 15 out of 61 facilities 
implementing the Program under the Primary Health Care 
were selected for audit. In total, the audit covered 198 units 
implementing the Programme (Fig. 1). 
Table I (Appendix) provides basic data on the working 
time of the facilities audited, the number of gynaecologists 
and midwives employed and the waiting time declared and 
confirmed by the auditors for Pap smears collection, as well 
as the number of Pap smears collected. 
The total number of Pap smear tests taken in the audited 
facilities outside the Programme was nearly twice as high as 
the number of Pap smears taken within the Programme in 
the analysed period (Fig. 2). The ratio of the number of Pap 
smears taken in particular facilities within the Programme 
to those taken outside the Programme varied greatly and 
ranged from 0.0 to 7.4.
There was a weak correlation between the number of 
working days per week and the declared and confirmed of 
waiting days for the collection of Pap smear (Spearman’s 
rank correlation coefficient –0.201 (p = 0.005) and –0.164 
(p = 0.021), respectively). There was no correlation between 
the number of Pap smears taken in both periods and the 
number of days in waiting for the collection of a Pap smear 
at the facility verified by the auditors (Spearman’s rank cor-
relation coefficient = 0.079 (p = 0.271)).
The waiting time for the result of the cervical screening 
test declared by the basic phase facilities was less than 15 
days in 146 clinics (73.7% of those audited). In the remaining 
52 (26.3%) it was longer than 15 days. 
Table II (Appendix) provides basic data on the percen-
tage of Pap smears classified as “unsuitable for evaluation”. 
In general, this percentage was very low except for several 
facilities. No statistically significant difference was found in 
Figure 1. Number of facilities audited in 2017 by voivodeships 
r The number of facilities in each voivodeship carrying out the basic 
phase amounts to approx. 12% 
r The number of facilities in the voivodeship carrying out the 
diagnostic phase amounts to 100%  
r The number of facilities in the voivodeship carrying out the phase 
of in-depth diagnostics amounts to 100%
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the percentage of Pap smears collected by gynaecologists 
and midwives classified as “unsuitable for evaluation” (Fig. 
3). These results apply to all the test samples collected at 
the facilities (within and outside the Programme). The per-
centage of Pap smears unsuitable for evaluation within the 
Programme was lower and amounted to 0.62%. 
A weak correlation was found between the percentage 
of Pap smears classified as “unsuitable for evaluation” and 
the total number of test samples collected by gynaeco-
logists (Spearman’s rank correlation coefficient = 0.136 
(p = 0.003)). No such correlation was observed among 
midwives (Spearman’s rank correlation coefficient = 0.117 
(p = 0.234)).
 In both audited periods the percentage of positive 
results did not exceed 3%.
The follow-up of patients with positive cervical scre-
ening test results obtained at audited basic phase facilities 
were presented in Table III (Appendix). 
The percentage of women in whom, in accordance with 
the criteria adopted in the Programme, further diagnosis 
was performed at the in-depth phase or the Pap smear was 
repeated within the Programme was 47.92% in all audited 
periods. About 8.5% of patients with positive results were 
admitted to further diagnostics under procedures reimbur-
sed by the NHF outside the Program. Service providers have 
data on follow-up of patients or have contacted another 
16.72% of patients with positive results of cervical screening 
test for whom data were not available in the SIMP and in 
the NHF reporting data on further diagnosis. There are no 
data on follow-up of 5.98% of patients with positive results 
of cervical screening test performed within the Programme 
(Fig. 4). Due to the inaccuracies in the post-audit protocols, 
the total number of patients for whom further fates were 
described does not equal the number of all patients with 
positive results of cervical screening test. During the ana-
lysis of the results, 22 (11%) erroneously filled in protocols 
were found.
The basic data on the equipment in facilities are presen-
ted in Table IV (Appendix). Almost all facilities were equipped 
with elements necessary for the proper collection of cytolo-
gical smears, i.e. a gynaecological chair, specula, disposable 
brushes, microscope slides and a fixative. 
Diagnostic phase
The audit covered 66 facilities implementing this dia-
gnostic stage. The largest number of cytological laboratories 
implementing this phase is located in Dolnośląskie, Małopol-
skie and Mazowieckie Voivodeships (each with 7 facilities). 
The smallest number is in the Opolskie Voivodeship, one lab 
only (Fig. 1). During the analysis of the results, inaccuracies 
were found in 30 (45.5%) audit protocols.
Figure 5 presents basic data on the number of cervical 
screening tests performed in the audited laboratories. Deta-
ils, including the breakdown by year, average, median, mini-
mum and maximum values, are given in Table V (Appendix).
In 2016, 14,589 positive result sand 3196 unsuitable 
for evaluation smears were found, representing 2.69% and 
0.56% respectively of the total number of tests evaluated 
in the Programme. In the first half of 2017, 6500 positive 
results and 1536 smears unsuitable for evaluation were 
found, representing 2.61% and 0.65% respectively of the 
34%  
85,715  
66%  
167,162  
smears collected within the Programme
smears collected outside the Programme
Figure 2. Number of Pap smear samples taken at the basic phase 
facilities audited
1.3% 
0.9% 
1.9% 
0.0%
0.2%
0.4%
0.6%
0.8%
1.0%
1.2%
1.4%
1.6%
1.8%
2.0%
Average percentage
Percentage of smears unsuitable for evaluation 
in audited facilities
Percentage of smears unsuitable for evaluation collected 
by gynaecologists in audited facilities
Percentage of smears unsuitable for evaluation collected 
by midwives in audited facilities
Figure 3. Average percentage of smears unsuitable for evaluation 
in the primary phase facilities audited — all tests (within the 
Programme and outside the Programme)
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total number of tests evaluated in the Programme in the 
analysed period (Fig. 6). 
Table VI contains numbers and percentages of positive 
cervical screening results found in the audited laboratories, 
while tables VII and VIII contain numbers and percentages 
of particular categories of abnormal cervical screening 
results found in the Bethesda system in the audited la-
boratories during the two analysed periods (all tables are 
enclosed). 
As part of internal quality control, cytological rescre-
ening is carried out by most cytology laboratories, but in 
different forms (Fig. 7). 86.4% of the laboratories perform a 
full re-evaluation of 10% of the evaluated cytology samples, 
24.2% of the laboratories perform a full re-evaluation of 
all samples, and 28.8% of the laboratories perform the re-
-evaluation in a different way. On average, the re-evaluation 
47.92%
(959)
8.31%
(168)
16.72%
(338) 
5.98% 
(121)
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
50.00%
Percentage of all positive results in the Programme* 
(in brackets: the number of women)
Women at whom further diagnostics was performed at 
in-depth phase or the Pap smear test was repeated as per 
SIMP recommendation
Women at whom neither further diagnostics was performed 
at in-depth phase nor the Pap smear test was repeated as per 
SIMP recommendation, but there are NHF report data available
Women for whom there is no in-depth phase/repeated test 
data available in SIMP and reporting data are not available in 
SIMP, but there are data on follow-up/contacts with the patient 
in the facility documentation
Women for whom there is no in-depth phase/repeated test 
data available in SIMP and reporting data are not available in 
SIMP, and there are no data on follow-up/contacts with the 
patient in the facility documentation
* Due to the inaccuracies in the post-audit protocols, the total 
number of patients for whom further follow-up was described 
does not equal the number of all patients with positive results 
of cervical screening test. 
Figure 4. Patients with positive results of cervical screening tests — 
follow-up
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Figure 5. Number of Pap tests taken at the diagnostic phase facilities 
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Figure 6. Percentage of test results, positive and unsuitable for 
evaluation in the audited facilities at the diagnostic phase (in relation 
to all tests within the Programme) 
Figure 7. Laboratories performing rescreening of cytology samples 
— diagnostic phase
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concerned 23.1% and 25.1% of samples in 2016 and the first 
half of 2017, respectively. Basic data on the percentage of 
the samples re-evaluated and on the discrepancies found 
between the initial and the re-evaluation are given in Table 
IX (Appendix). 
Staining with Papanicolaou technique is performed 
by 66 (100%) laboratories, the same number has “dotted” 
samples with positive results. One laboratory did not have 
Papanicolaou staining reagents, although all of them dec-
lared staining with the method mentioned above. Only 
41 (65.1%) laboratories keep electronic documentation, 
16 (25.4%) — both electronic and paper one, and 6 (9.5%) 
uses only paper one. There are no data for 3 laboratories 
in this respect. The continuity of numbering is ensured by 
63 (95.5%) laboratories, while in 3 (4.5%) the continuity of 
numbering of preparations is not kept. All audited labora-
tories are equipped with high quality microscopes. Correct 
archiving of samples in accordance with the regulation of 
the Minister of Health of 21 January 2009 amending the 
regulation on quality standards for medical diagnostic and 
microbiological laboratories and guidelines of the Polish 
Society of Pathologists (PSP Licence Commission) is carried 
out in 66 (100%) laboratories. Finding archived samples in 
an easy way can be done in 66 (100%) facilities. The mini-
mum, maximum, average and median time of finding an 
archived sample in the facilities is, respectively: 0.05 h, 48 h, 
1.6 h and 0.32 h. 
The general evaluation of the audit of cytological labo-
ratories implementing the diagnostic phase of the Cervical 
Cancer Prevention Programme and the data concerning the 
fulfilment of particular conditions of the Programme imple-
mentation are presented in Table X (Appendix). 40 (60.6%) 
of laboratories received recommendations after the audit. 
In-depth phase
The audit of the in-depth diagnostics stage of the Cervical 
Cancer Prevention Programme implemented in Poland was 
carried out for the second time since the beginning of the 
Programme. The audit covered 62 units implementing in-
depth diagnostic phase. The largest number of laboratories 
implementing this phase is located in Śląskie Voivodeship (12 
laboratories), whereas in Podlaskie Voivodeship there is not 
a single laboratory (Fig. 1). During the analysis of the results, 
inaccuracies were found in 14.5% post-audit protocols.
Table XI (Appendix) provides basic data on the working 
time of the facilities audited, the number of gynaecologi-
sts and midwives employed and the time of waiting for 
colposcopy declared and confirmed by the auditors. The 
declared and confirmed times of waiting for colposcopy 
were very similar. 
The number of colposcopies performed is shown in 
Table XII (Appendix). It shows that the number of colpo-
scopies performed outside the Programme is almost four 
times higher than the number of tests performed within 
the Programme (Fig. 8). The percentage of cervical biopsies 
performed in relation to colposcopies is presented in Table 
XIII (Appendix).
Data on the equipment and tools necessary to collect 
tissue samples for histopathological examination, available 
in the laboratories, are presented in Table XIV (Appendix). 3 
(4,8%) labs do not have biopsy forceps, while 4 (6,4%) labs 
do not have cervical scrapers and Lugol’s iodine. 10 (16.1%) 
laboratories did not have a sterilisation procedure in place, 
and at the same time 6 (9.7%) declared to use only single-use 
instruments. The minimum, maximum, mean and median 
times of waiting for the histopathological examination were 
respectively: 3.3, 28.9, 11.8 and 11.6 days. 
Discussion
Ensuring high quality procedures at each phase of or-
ganised cervical cancer screening is one of the key factors 
(apart from wide coverage of the target population and high 
quality treatment of detected pre-cancerous conditions) 
determining the effectiveness of secondary prevention [2]. 
Audits of the Programme service providers commissio-
ned by the COK were one of the elements of evaluation and 
attempts to ensure high quality of services offered under the 
Programme. Unfortunately, the complete lack of access to 
data collected at SIMP due to procedural reasons (between 
the ministry of Health and the National Health Fund) made 
the audit more complicated to a significant degree and 
certainly reduced the quality of audit and the reliability 
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of the data obtained. The post-audit reports provided by 
the auditors contained inaccuracies. Restoring access to 
SIMP data for COK staff is absolutely crucial to continue 
the quality control of services in the Cervical Cancer Pre-
vention Programme. This will allow for avoiding the need 
for the auditors’ obtaining data (collected in SIMP but not 
made available) directly from the service providers. More-
over, dedicated COK staff should have access to individual 
records and not only to aggregated data available in SIMP 
reports. Properly secured access to the required data should 
enable broad evaluation of the quality of procedures in 
the Programme, based, among others, on the calculation 
of quality indicators and measures recommended by the 
EU Guidelines [2].
The data from the audit of all 3 stages of the Programme 
clearly indicate that the number of Pap tests and colposco-
pies performed outside the Programme is much higher than 
the number of tests performed within the Programme in 
Poland. This is confirmed by the fact that opportunistic scre-
ening, less cost-efficient, is more common than organised 
screening, which has been observed since the beginning 
of the Programme implementation. Additionally, it should 
be emphasized that the number of cytological laboratories 
participating in the Programme is only a certain percenta-
ge (due to the lack of a central register) of all cytological 
laboratories operating in Poland, and the total number of 
tests conducted is unknown, but may reach several million 
annually. The number of colposcopies performed outside 
the Programme under the AOS is four times higher than in 
the Programme (only in the clinics performing the in-depth 
phase), and it is certainly a result of the lower pricing of 
procedures under the Programme in relation to the AOS. 
Significant differentiation of service providers’ preferences 
within the implementation of preventive procedures (Pro-
gramme vs AOS) indicates that by applying appropriate 
organisational solutions (appropriate pricing of Programme 
procedures, limiting access/benefit indications outside the 
Programme), it is possible to limit ineffective opportunistic 
screening. At the same time, it should be noted that PCP 
facilities are only authorised to carry out procedures under 
the Programme and do not carry out opportunistic scre-
ening financed by the National Health Fund. Moreover, in 
small PCP facilities with a limited number of patients aged 
25–59, the purchase of a gynaecological chair for the imple-
mentation of the Programme may not be cost-effective as 
PCP facilities may implement the Programme only within 
the scope of the list of their patients.
The lack of correlation between the number of collected 
Pap smears and the number of waiting days verified by the 
auditors may indicate that the number of days waiting for 
the collection of a Pap smear depends on the organisation 
of the facility and not on the demand for tests. This aspect 
requires further analysis.
A weak but statistically significant relationship between 
the percentage of “unsuitable for evaluation” smears and 
the total number of samples taken in facilities requires fur-
ther analysis and attention to be paid to the quality of the 
collection of Pap smears in large facilities.
The percentage of smears classified as “unsuitable for 
evaluation” is low. Since no differences were found in the 
percentage of cervical smears collected by gynaecologists 
and midwives assessed as “unsuitable for evaluation”, it is 
justified to support the collection of samples by midwives, 
especially in PCP facilities, where only screening within 
the Programme is performed. Further training by the COK 
and an increase in the number of midwives taking samples 
should increase the availability of cervical screening tests 
in the Programme. 
There are significant differences in the percentage of 
positive cervical screening tests and diagnosed pathological 
changes in individual laboratories, which indirectly indicates 
differences in the quality of smear evaluation. This is parti-
cularly true for ASC-US and LSIL smears. Currently, the lack 
of data concerning colposcopy and histological verification 
of individual positive cervical screening tests and access to 
data collected in the IT System for Monitoring Prevention 
precludes the final analysis and drawing conclusions regar-
ding the quality of diagnoses in individual laboratories. As 
part of internal quality control, cytological rescreening is 
commonly carried out by most cytology laboratories, but in 
different forms. On the other hand, external quality control 
of laboratories’ operation and individual cytotechnologists 
is recommended by the EU Guidelines and should be im-
plemented in Poland.
Considering the difficulties in accessing histopatho-
logical examinations, mainly related to a small number of 
pathomorphologists practising in Poland, the time of wa-
iting for the result of histopathological examination in the 
Programme should be considered acceptable. The condi-
tions affecting the quality of the tests, such as: the method 
of staining the samples, marking samples with positive 
results, continuity of samples numbering, access to high 
quality microscopes are fulfilled in almost all laboratories 
implementing the Programme, while the time of access to 
archived samples is varied and should be shortened in some 
audited laboratories.
We found large differences in the frequency of histopa-
thological verification performed by colposcopy facilities. 
This issue requires further analysis, searching for the reasons 
for such differentiation and examining the potential impact 
of this situation on the quality of final diagnoses and the 
impact on the fate of patients with abnormal results of 
cervical screening tests. There is a need to unify the rules 
of procedure for histopathological verification of abnormal 
cervical smears in laboratories offering the in-depth dia-
gnostics phase. The period of waiting for the colposcopy 
72
was relatively short and should not delay the diagnosis. The 
analysis shows that the percentage of patients subject to 
verification of cervical screening tests positive results under 
the Programme remains insufficient and a significant part of 
positive test results is still subject to further diagnosis out-
side the Programme. The percentage of recommendations 
implementation for in-depth diagnostics in previous years 
ranged from 29.7% to 50.5% [3]. The results of colposcopies 
and histopathological examinations performed outside the 
Program are not recorded in SIMP. This prevents the calcula-
tion of quality indicators and analysis of cytologic-histologic 
correlation.
The percentage of patients with cervical smear results, 
whose fate is unknown, is relatively low, but taking into ac-
count the estimated number of positive cervical screening 
results (approx. 14.5 thousand per year — a figure estimated 
on the basis of data on the number of tests coming from 
the diagnostic phase) at the national level, the number of 
these patients may reach 900 per year.
The equipment of the facilities implementing the basic 
phase of the Programme should be considered as good. 
Elements necessary for proper collection of smears were 
provided by the vast majority of facilities. Similar equipment 
audit results were obtained for cytology clinics. On the other 
hand, some of the clinics carrying out the in-depth phase of 
the Programme are not equipped and prepared to perform 
colposcopy-targeted biopsies or to perform endocarvical 
curretage. These clinics should be eliminated from the Pro-
gramme by the NHF’s terminating the contract.
Conclusions
1. The way in which the facilities implementing the Cervi-
cal Cancer Prevention Programme are audited, dictated 
by the total lack of access to data collected by COK and 
auditors, requires fundamental changes. Developing 
an agreement between the Ministry of Health and the 
National Health Fund regarding access to data for the 
COK is essential for evaluation of results obtained within 
the Programme, calculation of quality measures and 
scientific evaluation of other aspects of the Programme. 
2. Significanlty more Pap smears are collected within op-
portunistic screening as compared to the organised 
programme. Measures should be implemented to re-
duce opportunistic screening and to shift the stream of 
tests to the Programme. The great diversity of the ratio 
of tests performed within the Programme to tests per-
formed outside the Programme by healthcare providers 
proves that shifting the implementation of screening 
procedures to the Programme is potentially possible.
3. The quality of smear sample collection, measured as a 
percentage of “unsuitable for evaluation” is the same 
for gynaecologists and midwives.
4. Access to the Programme should be increased through 
training and certification of midwives, who will be enti-
tled to collect Pap smears both as part of the AOS and 
especially as part of the PCP, where only the Programme 
procedures are implemented, but the coverage of the 
Programme is very low.
5. External quality control of cervical screening tests sho-
uld be implemented in laboratories and for individual 
cytotechnologists.
6. Measures should be taken to shift the implementation 
of diagnostic procedures in patients with positive test 
results to an in-depth phase in the Programme, which 
allows for the recording of data and the analysis of fin-
dings obtained through cytological, colposcopy and 
histopathological evaluations in terms of their quality.
7. The criteria of indications for histopathological verifi-
cation for colposcopy at the in-depth phase should be 
unified and facilities where histopathological verifica-
tion is not performed should be eliminated from the 
Programme.
8. Measures should be taken to reach approximately 6% 
of patients whose follow-up is unknown after obtaining 
a positive result of a cervical screening test in the Pro-
gramme. There is no data on the follow-up of patients 
participating only in opportunistic screening, which 
is the predominant form of secondary prevention in 
Poland.
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Table I. Basic data on quality control of service providers implementing the basic phase of the Cervical Cancer Prevention Programme in 2016 and the 
first half of 2017
Parameter Min. Max. Mean Median
Number of the facility’s working days per week 3 6 5.3 6
Number of the facility’s working hours per week 2.5 69.5 28 25.8
Number of gynaecologists employed in the facility 0 12 2.6 2
Number of midwives employed in the facility (collecting Pap smears) 0 6 0.5 0
Number of days of waiting for the Pap smears collection, declared by providers 0 90 5 1
Number of days of waiting for the Pap smears collection, verified by the auditors 0 92 5.6 2.3
Number of Pap smears collected within the Programme for the whole 2016 0 1958 289 202.5
Number of Pap smears collected within the Programme in the first half of 2017 2 931 143.9 102
Number of Pap smears collected outside the Programme for the whole 2016 0 4214 550.1 334
Number of Pap smears collected outside the Programme in the first half of 2017 0 2141 298.4 182
Ratio of the number of Pap smears collected within the Programme to those 
collected outside the Programme in the whole audited period
0 7.4 1 0.6
Table II. Pap smears unsuitable for evaluation in the audited facilities of the basic phase of the Cervical Cancer Prevention Programme — all tests (within 
the Programme and outside it)
Parameter Min. Max. Mean Median
Percentage of Pap smears unsuitable for evaluation in the audited facilities 0 100 1.3 0.2
Percentage of Pap smears unsuitable for evaluation collected by 
gynaecologists in the audited facilities
0 33.7 0.9 0
Percentage of Pap smears unsuitable for evaluation collected by midwives in 
the audited facilities
0 100 1.9 0
Table III. Follow-up of women with abnormal cervical screening test findings
Parameter Period, N (%) Total, N (%)
01.01.–31.12.2016 01.01.–30.06.2017
Positive results of Pap tests (ASC-US, LSIL, ASC-H, HSIL, AGC, cancer) 1366 (2.39) 656
(2.30)
2022 (2.36)
Women with further in-depth diagnosis or repeated Pap tests as 
recommended by the SIMP
693
(50.73)
276
(42.07)
969
(47.92)
Women with neither further in-depth diagnosis nor Pap tests, as 
recommended by the SIMP, but with reporting data from the National Health 
Fund (NFZ)
115
(8.42)
53
(8.08)
168
(8.31)
Women for whom there is no in-depth diagnosis/repeated test data in the 
SIMP or reporting data in the SIMP but there are data on patient follow-up/
contacts in the facility documentation
195
(14.28)
143
(21.80)
338
(16.72)
Women for whom there is no in-depth diagnosis/repeated test data in the 
SIMP or reporting data in the SIMP and there are not follow-up data in the 
facility documentation
73
(5.34)
48
(7.32)
121
(5.98)
Appendix 
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Table IV. Equipment in audited facilities implementing the basic stage of the Cervical Cancer Prevention Programme
Piece of equipment Number of facilities having the 
piece of equipment in question 
Percentage of facilities having the 
piece of equipment in question
Gynaecological chair 196 99.0%
Disposable speculum 197 99.5%
Disposable cytology brushes for simultaneous Pap smear collection 
from the cervical orifice and the cervical canal)
197 99.5%
Single-sided matte-finished microscopic slides 196 99.0%
Cytofix (fixative) 195 98.5%
Alcohol 96% 7 3.5%
Table for disposable gynaecological examination instruments 197 99.5%
Shadowless lamp 197 99.5%
Wash basin with elbow-operated basin mixer (soap dispenser and 
hand disinfectant dispenser)
194 98.0%
Medical waste container 197 99.5%
Computer with Internet access 195 98.5%
Toilet seat 192 97.0%
Bidet 191 96.5%
Wash basin 193 97.5%
Table V. Figures for Pap tests performed in the periods under consideration
Parameter Number of Pap tests and 
gynaecological examinations 
performed within the Programme
Number of Pap tests and 
gynaecological examinations 
performed outside the 
Programme
Number of all Pap tests: within the 
Programme, outside the Programme, and 
Pap tests other than gynaecological ones
Period from 
01.01.2016 to 
31.12.2016
Min. 274
Max. 49,598
Total: 544,352
Median: 5264
Mean: 8248
Min. 232
Max. 166,974
Total: 1,364,428
Median: 10,714
Mean: 20,991
Min. 1104
Max. 185,728
Total: 2,053,594
Median: 15,925
Mean: 31,594
Period from 
01.01.2017 to 
30.06.2017
Min. 112
Max. 23,805
Total 257,288
Median: 2430
Mean: 3898
Min. 103
Max. 95,617
Total: 664,560
Median: 5314
Mean: 10,224
Min. 603
Max. 104,852
Total: 984,080
Median: 8078
Mean: 15,140
Table VI. Numbers and percentages of positive Pap test results diagnosed in audited cytology laboratories
Parameter Number of positive test results performed 
within the Programme for all laboratories
Percentage of positive test results performed 
within the Programme for all laboratories
Period from 01.01.2016 to 31.12.2016 Min. 6
Max. 1939
Total: 14,589
Median: 125
Mean: 221
Min. 0.52
Max. 9.32
Median: 2.31
Mean: 2.69
Period from 01.01.2017 to 30.06.2017 Min. 1
Max. 807
Total: 6500
Median: 51
Mean: 98
Min. 0.71
Max. 8.39
Median: 2.31
Mean: 2.61
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Table VII. Numbers and percentages of particular categories of abnormal results of Bethesda system Pap tests diagnosed in the Programme in the 
audited laboratories in 2016
PARAMETER Number %
Min. Max. Total Median Mean Min. Max. Median Mean
ASC-US 1 377 6054 52 91.73 0.11 5.14 0.90 1.21
LSIL 0 1457 5260 37 79.70 0.00 4.08 0.69 0.82
ASC-H 0 108 1169 8.5 17.71 0.00 0.73 0.19 0.21
HSIL 0 144 1508 12 22.85 0.00 1.73 0.26 0.30
Squamous cell carcinoma 0 8 97 1 1.47 0.00 0.13 0.01 0.02
AGC 0 61 479 3 7.26 0.00 2.37 0.06 0.13
Adenocarcinoma in situ (AIS) 0 5 5 0 0.08 0.00 0.01 0.00 0.00
Adenocarcinoma 0 3 4 0 0.06 0.00 0.02 0.00 0.00
Other cancers 0 2 4 0 0.06 0.00 0.05 0.00 0.00
Pap smear samples unsuitable for 
evaluation
0 450 3196 11 48.42 0 3.08 0.31 0.56
Table VIII. Numbers and percentages of particular categories of abnormal results of Bethesda system Pap tests diagnosed in the Programme in the 
audited laboratories in the first half of 2017
PARAMETER Number %
Min. Max. Total Median Mean Min. Max. Median Mean
ASC-US 0 175 2679 21 40.60 0.00 5.27 0.86 1.18
LSIL 0 606 2293 18 34.74 0.00 3.32 0.66 0.76
ASC-H 0 47 601 5 9.12 0.00 0.65 0.18 0.23
HSIL 0 77 696 5.5 10.55 0.00 1.90 0.27 0.32
Squamous cell carcinoma 0 4 42 0 0.64 0.00 0.24 0.00 0.03
AGC 0 20 183 1 2.78 0.00 1.79 0.05 0.10
Adenocarcinoma in situ (AIS) 0 5 6 0 0.09 0.00 0.03 0.00 0.00
Adenocarcinoma 0 1 3 0 0.05 0.00 0.03 0.00 0.00
Other cancers 0 1 1 0 0.02 0.00 0.01 0.00 0.00
Pap smear samples unsuitable for 
evaluation
0 218 1536 6 23.27 0 8.82 0.28 0.65
Table IX. Basic data on discrepancies between the primary and secondary evaluation of Pap smear samples found during the internal quality control of 
the evaluation of Pap smear samples in the audited laboratories
Parameter Percentage of tests re-evaluated in quality 
control procedures
Percentage of discrepancies detected 
between primary and secondary 
evaluation of samples in quality control 
procedures
Period from 01.01.2016 to 31.12.2016 Min. 7.2
Max. 100
Median. 10.5
Mean. 23.1
Min. 0
Max. 13.5
Median. 0.3
Mean. 1.5
Period from 01.01.2017 to 30.06.2017 Min. 6.9
Max. 100
Median. 11.5
Mean. 25.1
Min. 0
Max. 12.8
Median. 0.3
Mean. 1.4
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Table X. The general evaluation of the audit of cytological laboratories implementing the diagnostic phase of the Cervical Cancer Prevention Programme 
and the data concerning the fulfilment of particular conditions of the Programme implementation
Criteria for the provision of services guaranteed by the Cervical Cancer Prevention Programme — diagnostic phase in accordance with 
the regulation of the Minister of Health dated August 5, 2016 on detailed criteria for selection of offers in the procedure for conclusion of 
agreements on provision of healthcare services and the Regulation of the Minister of Health of 2013 on guaranteed services within the scope 
of health programmes
Criterion Number and percentage of facilities 
meeting this criterion
Medical diagnostic laboratory entered in the register kept by the National Council of Laboratory 
Diagnostics or a pathomorphological facility with a cytological lab
66 (100%)
A doctor specializing in pathomorphology or pathological anatomy 66 (100%)
Lab cytotechnologists with a title of specialist in medical cytomorphology or a proven ability and 
experience relevant to the performance of cytological tests
65 (100%) — 1 centre, no data available
Medical equipment and instruments: high-quality microscopes capable of giving a magnification of at 
least 400 times
66 (100%)
Performed by each person* evaluating the samples in at least 7000 Pap tests a year  
* qualifications of the staff in accordance with the regulation (the number of tests carried out refers to the 
whole operations, also outside the contract with the National Health Fund)
47 (73.4%) — 2 centres, no data 
available
Performing 15,000 Pap tests at the laboratory** 
**refers to the whole operations, also outside the contract with the National Health Fund)
45 (68.2%)
Sending the result to the clinic that collected the test material within seven working days from the date 
of the sample reception
63 (96.9%) — 1 centre, no data 
available
Detailed, supplementary conditions concerning the services provision terms in accordance with the order no. 99/2015/DSOZ of the President 
of the National Health Fund of 22 December 2015 — requirements for tenderer at the diagnostic phase
Condition Number and percentage of facilities 
meeting this criterion
A cytological sample other than with a negative result must be evaluated in two steps: at least by a 
doctor specialising in pathomorphology or pathological anatomy
66 (100%)
Table XI. Basic data on the working time of facilities and the number of employees at healthcare providers executing the phase of in-depth diagnostics 
of the Cervical Cancer Prevention Programme in 2016 and the first half of 2017
Parameter Min. Max. Mean Median
Number of the facility’s working days per week 1 6 3.5 4
Number of the facility’s working hours per week 1 60 21.5 12
Number of gynaecologists employed in the facility (2016) 1 7 1.8 2
Number of gynaecologists employed in the facility (2017) 1 7 1.8 1.5
Number of days of waiting for colposcopy, declared by healthcare 
providers
0 30 7.3 7
Number of days of waiting for colposcopy, verified by auditors 0 25 8.3 6.8
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Table XII. Number of colposcopies performed in the laboratories during the audited periods
01.01.2016–31.12.2016*
Within the Programme Outside the Programme
Number: 
Min. 0
Max. 573
Mean: 46.2
Median: 22.5
Total for all facilities: 2740
Number:
Min. 0
Max. 1333
Mean: 155.8
Median: 38.5
Total for all facilities: 9037
01.01.2017–30.06.2017*
Within the Programme Outside the Programme
Number:
Min. 1
Max. 220
Mean: 20.3
Median: 10
Total for all facilities: 1189
Number:
Min. 0
Max. 684
Mean: 79.3
Median: 25
Total for all facilities 4599
*4 laboratories did not provide any data on the number of tests performed outside the Programme
Table XIII. Numbers of biopsies performed in the laboratories and their percentage in relation to the number of colposcopies performed in the audited 
periods
01.01.2016–31.12.2016*
Number of cervical biopsies Percentage of biopsies in relation to the number of colposcopies
Number: 
Min. 0
Max. 547
Mean: 36.1
Median: 17
Total for all facilities: 2236
Number:
Min. 0%
Max. 100%
Mean: 30.4%
Median: 16.3%
01.01.2017–30.06.2017*
Number of cervical biopsies Percentage of biopsies in relation to the number of colposcopies
Number: 
Min. 0
Max. 207
Mean: 15.5
Median: 6.5
Total for all facilities: 962
Number:
Min. 0%
Max. 100%
Mean: 28.4%
Median: 15.4%
*4 laboratories did not provide any data on the number of tests performed outside the Programme
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Table XIV. Equipment in audited facilities implementing the in-depth phase of the Cervical Cancer Prevention Programme
Piece of equipment Number of facilities having the piece 
of equipment in question
Percentage of facilities having the 
piece of equipment in question
Optical colposcope with a valid technical passport 62 100%
Contrasting filter in a colposcope 59 95.2%
Disposable specula 62 100%
Sterilised reusable specula 29 46.8%
Tweezers 61 98.4%
Biopsy forceps for colposcopy-targeted biopsy 59 95.2%
Cervical scrapers 58 93.6%
Buffered formalin 59 95.2%
Containers for tissue material fixation 61 98.4%
Sterile swabs 62 100%
Physiological saline solution 62 100%
Acetic acid 3–5% 62 100%
Lugol’s iodine 58 93.6%
Electrocautery apparatus and ball coagulation electrodes for post-
biopsy haemostasis
49 79.0%
Coagulating laser 17 27.4%
Autoclave 48 77.4%
Separate sterilisation room 50 80.7%
Sterilisation procedure in place 52 83.9%
External sterilisation outside the facility 11 17.7%
Use of disposable instruments only 6 9.7%
Availability of HPV diagnostics 42 67.7%
